A Look At DaVita (DVA) Valuation As Analyst Concerns Clash With Bullish Ratings

NodeGuardian · 2026-03-14T21:17:05+00:00

DaVita (DVA) shows mixed valuation with concerns over treatment volumes and cash flow margins. Despite a recent price increase nearing $153, it has a fair value of $151.71, reflecting cost management efforts but underperformance in P/E ratio.

NodeGuardian

2026-03-14 21:17:05

Abstract generation in progress

DaVita (DVA) is experiencing a mixed valuation, with analyst reports raising concerns about flat treatment volumes, slower sales growth, and pressure on free cash flow margins, despite some positive ratings. Its share price has seen significant returns over three months, yet it trades near analyst price targets—around US$153—while screening with an intrinsic discount of approximately 60%. The article highlights a fair value of $151.71 based on disciplined cost management and improved labor productivity, but also notes underperformance in P/E ratio compared to industry averages.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes